Physician profile
James Ong
NPI 1912955980
$29,173.95
in general payments reported to CMS, 2019-2025
37 companies · $7,532 in 2025
The $7,532 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,970 · 2020: $3,184 · 2021: $3,805 · 2022: $3,322 · 2023: $4,875 · 2024: $4,485 · 2025: $7,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Travel and Lodging: $2,509 · Consulting Fee: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,133.52 |
| Travel and Lodging | $2,509.30 |
| Consulting Fee | $1,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $7,532.11 | 2021-2025 | Reveal Linq, Linq II, Azure Xt Dr Mri Surescan |
| Abbott Laboratories | $6,761.26 | 2019-2025 | Gallant, Jot Dx, Aveir |
| Biosense Webster, INC. | $3,647.36 | 2019-2025 | Qdot Micro Catheter, Carto 3, Octaray Mapping Catheter |
| Janssen Pharmaceuticals, INC | $1,364.04 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $1,256.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,123.61 | 2021-2025 | Jardiance |
| Boston Scientific Corporation | $1,063.42 | 2019-2025 | Rhythmia Mapping System, General - Therapies, Vigilant X4 Crt-D |
| E.R. Squibb & Sons, L.L.C. | $933.79 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $742.10 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $608.07 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $538.00 | 2021-2024 | Verquvo |
| Atricure, INC. | $521.55 | 2021-2025 | Synergy Ablation System, Atriclip Laa Exclusion System |
| Astrazeneca Pharmaceuticals Lp | $482.53 | 2023-2025 | Farxiga, Wainua |
| Sanofi-Aventis U.S. LLC | $355.48 | 2019-2024 | |
| Alnylam Pharmaceuticals INC. | $252.67 | 2022-2025 | Amvuttra, Onpattro |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acutus Medical, INC. | $231.45 | 2022-2023 | |
| Amgen INC. | $181.00 | 2019-2025 | Repatha, Repatha |
| Impulse Dynamics (USA) INC. | $173.72 | 2023-2024 | Optimizer, Optimizer |
| Bridgebio Pharma, INC. | $153.66 | 2025 | Attruby |
| Cordis US Corp. | $152.24 | 2024-2025 | Mynx Venous Vcd, Mynx Control Venous |
| Biotronik INC. | $135.81 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.68 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $108.80 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $108.07 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $101.58 | 2021-2022 | |
| Bardy Diagnostics, INC. | $78.11 | 2020 | |
| Novo Nordisk INC | $67.94 | 2024-2025 | Wegovy |
| Cvrx, INC. | $59.39 | 2024 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $51.79 | 2023-2024 | Inpefa |
| Edwards Lifesciences Corporation | $51.37 | 2025 | Sapien 3 Ultra Resilia |
| Convatec INC. | $49.83 | 2025 | |
| Heartflow, INC. | $42.03 | 2022-2024 | |
| Kiniksa Pharmaceuticals, Ltd. | $33.21 | 2023 | Arcalyst |
| Baxter Healthcare | $27.86 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Elutia, INC. | $27.27 | 2021 | |
| Kci USA, INC. | $22.56 | 2022 | |
| Medicomp INC | $16.59 | 2023 | Telepatch Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.